As our understanding of immune function regulators and the effects of the tumour microenvironment on immune cells improves, increasingly more complex cell engineering is being employed to improve the efficacy of cellular immunotherapies.
In this poster, we demonstrate high base editing efficiency of the Pin-point™ base editing platform by assessing the editing purity at all target sites and characterising the occurrence of DNA and RNA off targets, as well as genomic structural variants.
The Pin-point platform technology is available for clinical study and commercialization under a commercial license from Revvity. Pin-point reagents are available for research use only.
One-step generation of allogeneic CAR-T cells by simultaneous multiplex knockout and site-specific transgene integration with the Pin-point™ base editing platform